Nanoparticles-mediated mitochondrial relocation of lipid-lowering drugs shape energy metabolism to conquer acquired immune resistance
Drug Resistance Updates · 2026
DOI: 10.1016/j.drup.2025.101323 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Cheng Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Third Xiangya Hospital of Central South University, Changsha 410013, China. Hauptthemen laut MEDLINE: Mitochondria, Energy Metabolism, Nanoparticles, Hypolipidemic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, Wenzhou Medical University, Hunan Provincial Natural Science Foundation.
Abstract (Originalsprache)
CD276, is a fatal recently discovered immune checkpoint proteins of B7 family. Due to the not clearly uncovered signal pathways that involved in the expression of CD276 in tumors, few strategies were discovered to regulate CD276. Here, we newly discovered that abnormal tumor mitochondrial activation played a vital important role in raising CD276 expression through targeting AMPK/mTOR signal pathway. Then, it was also revealed that clinical usable lipid-lowering drugs with mitochondria oxidative phosphorylation (OXPHOS) and glycolysis inhibiting capacity, like fenofibric acid (FFA), exhibited desired programmed death ligand-1 (PD-L1) and CD276 co-suppression capacity. To better deliver FFA to tumor mitochondria, IR-FFA was synthesized by linking the mitochondria-targeting heptamethylene cyanine IR-68 with FFA, followed by self-assembly with albumin (Alb) to create IR-FFA@Alb nanoparticles. By doing so, the dosage needed for IR-FFA@Alb to depress CD276 and PD-L1 expression was 100 times lower than free FFA. Then, IR-FFA@Alb monotherapy effectively inhibited tumor growth both in vitro and in vivo. Moreover, the combination therapy of IR-FFA@Alb nanoparticles and radiotherapy (RT) effectively avoid the frequently occurred immune tolerance phenomenon of RT by co-depression CD276 and PD-L1. These results altogether showed the possibility of using lipid-lowering drugs as multi-functional immune checkpoint inhibitors to sensitize tumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Third Xiangya Hospital of Central South University, Changsha 410013, China.
- Department of Urology, The Second Xiangya Hospital of Central South University, Changsha 410011, China.
- State Key Laboratory of Ophthalmology, Optometry and Vision Science, School of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou 325027, China.
- State Key Laboratory of Ophthalmology, Optometry and Vision Science, School of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou 325027, China; Wenzhou Institute, Univers…
- State Key Laboratory of Ophthalmology, Optometry and Vision Science, School of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou 325027, China. Electronic address: zhouza…
- Department of Radiotherapy, Taizhou Central Hospital(Taizhou University Hospital), No.999 Donghai Avenue, Economic Development District, Taizhou 318000, China. Electronic address: 13957608158@139.com.
Förderung
- National Key Research and Development Program of China
- Wenzhou Medical University
- Hunan Provincial Natural Science Foundation
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Li, C., Xiong, W., Liu, J., Li, K., Wang, H., Wang, Z., Liu, F., Shen, J., Zhou, Z., Ying, S., & Wang, L. (2026). Nanoparticles-mediated mitochondrial relocation of lipid-lowering drugs shape energy metabolism to conquer acquired immune resistance. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101323
Vancouver
Li C, Xiong W, Liu J, Li K, Wang H, Wang Z, et al. Nanoparticles-mediated mitochondrial relocation of lipid-lowering drugs shape energy metabolism to conquer acquired immune resistance. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2025.101323
BibTeX
@article{Li2026,
author = {Li, Cheng and Xiong, Wei and Liu, Jiahao and Li, Ke and Wang, Haoxiang and Wang, Zhengxiang and Liu, Feiyu and Shen, Jianliang and Zhou, Zaigang and Ying, Shenpeng and Wang, Long},
title = {Nanoparticles-mediated mitochondrial relocation of lipid-lowering drugs shape energy metabolism to conquer acquired immune resistance},
journal = {Drug Resistance Updates},
year = {2026},
doi = {10.1016/j.drup.2025.101323}
}
EUVIMED